Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy

Antifungal prophylaxis can be recommended in patients undergoing induction chemotherapy for acute myeloid leukemia and treatment for grade 2 or greater or chronic extensive graft versus host disease. The evidence for prophylaxis is less clear in other clinical settings although certain groups such as patients with prolonged neutropenia after stem cell transplants using bone marrow or cord blood sources and with impaired cell mediated immunity secondary to treatments such as Alemtuzumab are at high risk. The decision to use prophylaxis and which agent to use will be influenced by effectiveness, number needed to treat and the likelihood of toxicity and drug interactions. The availability of rapid diagnostic tests for fungal infection and institutional epidemiology will also influence the need for and choice of prophylaxis. Whilst prophylaxis can be beneficial, it may impede the ability to make a rapid diagnosis of fungal infection by reducing the yield of diagnostic tests and change the epidemiology of fungal infection. As non‐culture based diagnostic tests are refined and become more available there may be a shift from prophylaxis to early diagnosis and treatment.

[1]  M. Robin,et al.  Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. , 2008, International journal of antimicrobial agents.

[2]  A. Grigg,et al.  Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy , 2008, Transplant infectious disease : an official journal of the Transplantation Society.

[3]  L. Leibovici,et al.  Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Dipersio,et al.  Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients. , 2007 .

[5]  S. Tong,et al.  Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient , 2007, Transplant infectious disease : an official journal of the Transplantation Society.

[6]  R. Bouabdallah,et al.  High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation , 2007, Bone Marrow Transplantation.

[7]  Raoul Herbrecht,et al.  Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[9]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[10]  B. D. de Pauw,et al.  Prophylaxis and aspergillosis--has the principle been proven? , 2007, The New England journal of medicine.

[11]  P. Moreau,et al.  Lung Resection for Invasive Pulmonary Aspergillosis in Neutropenic Patients with Hematologic Malignancies: Long Term Results in Thirty Two Cases. , 2006 .

[12]  H. Einsele,et al.  Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantati , 2006, Blood.

[13]  D. Marriott,et al.  Active Surveillance of Candidemia, Australia , 2006, Emerging infectious diseases.

[14]  M. Slavin,et al.  Antifungal strategies for managing invasive aspergillosis: The prospects for a pre-emptive treatment strategy. , 2006, Medical mycology.

[15]  E. Thiel,et al.  Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  D. Kontoyiannis,et al.  Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  H. Prince,et al.  Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab * , 2006, British journal of haematology.

[18]  D. Kontoyiannis,et al.  Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). , 2006, Haematologica.

[19]  L. Pagano,et al.  Design and Methods , 2022 .

[20]  F. Donnerstag,et al.  Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies , 2006, Supportive Care in Cancer.

[21]  P. Gøtzsche,et al.  Misleading statements in industry-sponsored meta-analysis of itraconazole. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Wingard,et al.  Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia. , 2005, Clinical advances in hematology & oncology : H&O.

[23]  R. Hills,et al.  Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Leisenring,et al.  Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  B. Wassmann,et al.  Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia , 2005, Annals of Hematology.

[26]  Russell E. Lewis,et al.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.

[27]  N. Kröger,et al.  Haemopoietic Cell Transplantation of Patients with a History of Deep or Invasive Fungal Infection during Prophylaxis with Liposomal Amphotericin B , 2005, Acta Haematologica.

[28]  K. Wannemuehler,et al.  Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. , 2005, Medical mycology.

[29]  A. Gratwohl,et al.  Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. , 2004, Chest.

[30]  D. Kontoyiannis,et al.  Invasive aspergillosis in patients with solid tumors , 2004, Cancer.

[31]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  J. Wingard.  Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  J. Szer,et al.  A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.

[34]  L. Bartelt,et al.  Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  G. Byrnes,et al.  Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.

[36]  C. Cordonnier,et al.  Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients , 2004, Bone Marrow Transplantation.

[37]  J. Mehta,et al.  Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice , 2004, Bone Marrow Transplantation.

[38]  F. Marty,et al.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. , 2004, The New England journal of medicine.

[39]  W. Leisenring,et al.  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.

[40]  W. Leisenring,et al.  Cyclophosphamide metabolism is affected by azole antifungals. , 2004, Blood.

[41]  H. Kantarjian,et al.  Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy , 2004, Cancer.

[42]  B. Djulbegovic,et al.  Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Maris,et al.  Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. , 2003, Blood.

[44]  M. Territo,et al.  Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial , 2003, Annals of Internal Medicine.

[45]  M. Boeckh,et al.  Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. , 2002, Blood.

[46]  E. Bow,et al.  Antifungal prophylaxis for severely neutropenic chemotherapy recipients , 2002, Cancer.

[47]  J. Wingard,et al.  Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital , 2002, Bone Marrow Transplantation.

[48]  J. Baddley,et al.  Invasive mold infections in allogeneic bone marrow transplant recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  M. Avison,et al.  Interscience Conference on Antimicrobial Agents and Chemotherapy , 2001 .

[50]  M. Boeckh,et al.  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000, Blood.

[51]  H. Prentice,et al.  Towards a targeted, risk‐based, antifungal strategy in neutropenic patients , 2000, British journal of haematology.

[52]  T. C. White,et al.  Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.

[53]  D. De Bacquer,et al.  Impact of previous aspergillosis on the outcome of bone marrow transplantation. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  R. Moore,et al.  Using Numerical Results from Systematic Reviews in Clinical Practice , 1997, Annals of Internal Medicine.

[55]  J. Szer,et al.  Multiple granulocyte transfusions facilitating successful unrelated bone marrow transplantation in a patient with very severe aplastic anemia complicated by suspected fungal infection. , 1995, Bone marrow transplantation.

[56]  M. Levenstein,et al.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.

[57]  P. Beatty,et al.  The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. , 1994, The American journal of medicine.

[58]  H. Horowitz,et al.  Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial , 1993, Annals of Internal Medicine.

[59]  G. Rosner,et al.  Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. , 1992, The Journal of infectious diseases.

[60]  J. L. Goodman,et al.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.

[61]  J. Karp,et al.  An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. , 1988, The American journal of medicine.